Blood Eosinophils From CRSwNP Patients Present Higher CCR3 Expression Associated With Olfactory Recovery After Treatment With Dupilumab

This was a Phase IV observational cohort study conducted at Lille University Hospital.Patients with severe CRSwNP were included before treatment with dupilumab, and data were collected at base- Key Points• Blood eosinophils show increased CCR3 expression in patients with CRSwNP and associated asthma.• Dupilumab treatment progressively lowers CCR3 expression on blood eosinophils, ultimately restoring levels similar to those observed in healthy controls.• Higher baseline CCR3 expression on blood eosinophils is associated with better ETOC.I scores after 18 months of treatment.line (M0) and at 3 (M3), 6 (M6), 12 (M12), and 18 months (M18) post-treatment (Figure S1 ).The study adhered to the Declaration of Helsinki, the French Public Health Code, and European Union Good Clinical Practice guidelines.Written informed consent was obtained from all participants.The protocol was approved by the French Committee for the Protection of Individuals and registered at ClinicalTrials.gov(NCT05228041).Non-asthmatic, nonsmoking, and non-allergic healthy controls were also included, as provided by the PLEIAD protocol (NCT04187976).Clinical response was determined at each time point and evaluated using the Sino-Nasal Outcome Test-22 (SNOT-22) quality of life questionnaire (0-110) and visual analogue scales (VAS) for individual nasal symptoms (nasal obstruction, dysosmia) and for